Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

1.5K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.5K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

1.9K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.9K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

2.3K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.3K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

1.7K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.7K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

2.2K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
2.2K
Allergic Reactions02:06

Allergic Reactions

33.4K
Overview
33.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A phase I, randomized, dose-escalation clinical trial of the anti-IgE humanized monoclonal antibody LP-003 in healthy subjects.

Combinatorial chemistry & high throughput screening·2026
Same author

Comparative Cochlear-Vestibular Aging Reveals Age-Aligned Mitochondrial Ultrastructural Burden, Mitophagy-Autophagy Remodeling, Synaptic Uncoupling, and Sensory Functional Decline.

Aging cell·2026
Same author

Cumulative adverse childhood experiences and parent-reported allergic conditions and asthma among U.S. children: A nationally representative study.

The American psychologist·2026
Same author

Efficacy and Safety of Dupilumab in Chinese Adult Patients With Chronic Rhinosinusitis With Nasal Polyps: A Randomized, Placebo-Controlled, Phase III Trial.

Allergy·2026
Same author

Aging, Genetic Susceptibility and Risk of Chronic Inflammatory Upper Airway Diseases: Finding From A Prospective Cohort Study.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2026
Same author

Butyrylated Starch Attenuates Antibiotic-Exacerbated Allergic Rhinitis by Restoring the Gut Microbiota and Barrier Function in Mice.

Food science & nutrition·2026
Same journal

Real-World Evaluation of AI-Assisted Readout of Skin Prick Automated Test Results.

Allergy·2026
Same journal

Serotonin Degradation and Lipid Metabolism Regulate Human Tc2 Cell Effector Functions.

Allergy·2026
Same journal

Protein Corona-Coated Crystal Silica From Sandstorms Amplifies Allergic Rhinitis by Regulating Epithelial Integrity in Mice and Human Nasal Epithelia.

Allergy·2026
Same journal

EAACI Guidelines on Environmental Science for Allergy and Asthma-Evidence-Based Recommendations for Prevention and Public Health Action to Mitigate the Impact of Pollen Exposure on Respiratory Allergy.

Allergy·2026
Same journal

Diet-Microbiome-Immune Interactions at the Gut Mucosa in Food Allergy: Mechanisms, Gaps, and Therapeutic Implications.

Allergy·2026
Same journal

Melittin in AllergoOncology: From Honey Bee Venom to Anti-Cancer Therapeutic Innovation-An EAACI Position Paper.

Allergy·2026
See all related articles

Related Experiment Video

Updated: Mar 25, 2026

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
03:40

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Published on: December 20, 2024

1.7K

Chinese Position Paper on Biologic Therapy for Allergic Rhinitis.

Yuan Zhang1,2,3,4,5, Jingyun Li2,3,4,5, Xian Li1,2,3,4,5

  • 1Department of Allergy, Beijing Tongren Hospital, Capital Medical University, Beijing, China.

Allergy
|March 24, 2026
PubMed
Summary
This summary is machine-generated.

Biologic therapies offer new hope for allergic rhinitis (AR) patients with uncontrolled symptoms. This paper reviews evidence and provides recommendations for using these advanced treatments, particularly for seasonal allergic rhinitis (SAR).

Keywords:
Chinaallergic rhinitisbiologicsmonoclonal antibodytreatment

More Related Videos

Author Spotlight: Advancing Allergic Rhinitis Research with Multicolor Immunofluorescence
06:08

Author Spotlight: Advancing Allergic Rhinitis Research with Multicolor Immunofluorescence

Published on: September 22, 2023

2.8K
A Component-resolved Diagnostic Approach for a Study on Grass Pollen Allergens in Chinese Southerners with Allergic Rhinitis and/or Asthma
06:34

A Component-resolved Diagnostic Approach for a Study on Grass Pollen Allergens in Chinese Southerners with Allergic Rhinitis and/or Asthma

Published on: June 4, 2017

10.6K

Related Experiment Videos

Last Updated: Mar 25, 2026

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
03:40

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Published on: December 20, 2024

1.7K
Author Spotlight: Advancing Allergic Rhinitis Research with Multicolor Immunofluorescence
06:08

Author Spotlight: Advancing Allergic Rhinitis Research with Multicolor Immunofluorescence

Published on: September 22, 2023

2.8K
A Component-resolved Diagnostic Approach for a Study on Grass Pollen Allergens in Chinese Southerners with Allergic Rhinitis and/or Asthma
06:34

A Component-resolved Diagnostic Approach for a Study on Grass Pollen Allergens in Chinese Southerners with Allergic Rhinitis and/or Asthma

Published on: June 4, 2017

10.6K

Area of Science:

  • Immunology
  • Allergology
  • Pharmacology

Background:

  • Allergic rhinitis (AR) is a widespread nasal condition with significant public health implications.
  • Existing treatments often inadequately control symptoms for many patients.
  • Biologic therapies targeting type 2 inflammation have emerged for difficult-to-treat AR.

Purpose of the Study:

  • To evaluate the efficacy and safety of biologic agents in AR management.
  • To provide recommendations for the appropriate use of biologics in AR.
  • To support the integration of biologics into clinical practice for uncontrolled AR.

Main Methods:

  • A multidisciplinary expert panel convened to review current evidence.
  • Evaluation of international and regional clinical studies on biologic therapies for AR.
  • Focus on evidence for seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR).

Main Results:

  • Biologic therapies show promise for patients with poorly controlled AR, especially SAR.
  • Novel agents like stapokibart are advancing treatment options.
  • Evidence for biologics in perennial allergic rhinitis (PAR) is still limited.

Conclusions:

  • Biologics represent a valuable therapeutic option for specific AR patient populations.
  • Standardized, evidence-based recommendations are needed for biologic use in AR.
  • Further research is warranted, particularly for PAR, to optimize biologic therapy integration.